Transapical transcatheter aortic valve implantation: Follow-up to 3 years

Abstract

Our outcome suggests that transapical transcatheter aortic valve implantation provides sustained clinical and hemodynamic benefits for up to 36 months in selected high-risk patients with symptomatic severe aortic stenosis.

Transcatheter Aortic Valve-in-Valve Implantation for Patients With Degenerative Surgical Bioprosthetic Valves

“…Durability of both SAPIEN and CoreValve VIV implants has been reported out beyond 3 years. 47, 48 Our group has documented durability of THV implants in native aortic valves and mitral prostheses out beyond 5 years. 49, 50 Although encouraging, incomplete THV expansion can be expected to result in perturbation of leaflet mechanics, coaptation, flow dynamics and leaflet/frame contact.…”

Innovations in Therapies for Heart Valve Disease

“…While little long-term data exist regarding TA-TAVI, mid-term data suggest that the hemodynamic and clinical benefits of the procedure are durable out to 3 years. 45 In patients who survived longer than 30 days, the 2-year and 3-year survival in one series was 79.8% and 69.8%, respectively. Mean New York Heart Association classification decreased from 3.3 preoperatively to 1.8 postoperatively, and the mean transvalvular gradient on echocardiography at 3 years was 10.3 mmHg.…”

Clinical trial experience with transcatheter aortic valve insertion

“…The PARTNER trial demonstrated an absolute 20% reduction in mortality at 1 year when compared to standard medical in this ultra high risk population. Sustainability of these results is further supported by registry data demonstrating survival rates of 66 and 58% at 2 and 3 years respectively [28]. Support for expanding this argument to lower risk populations (operable patients with high surgical risk) comes when one considers data from the Leipzig group; the investigators report their experience with octogenarians that underwent SAVR stratified by EuroSCORE.…”